Open Access Research article

Caspase-1 genetic variation is not associated with Alzheimer's disease risk

José Luis Vázquez-Higuera1, Eloy Rodríguez-Rodríguez1, Pascual Sánchez-Juan1, Ignacio Mateo1, Ana Pozueta1, Ana Martínez-García2, Ana Frank3, Fernando Valdivieso2, José Berciano1, María J Bullido2 and Onofre Combarros1*

Author Affiliations

1 Neurology Service and CIBERNED, "Marqués de Valdecilla" University Hospital (University of Cantabria), Santander, Spain

2 Molecular Biology Department and CIBERNED, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Madrid, Spain

3 Neurology Service and CIBERNED, Hospital Universitario La Paz (UAM), Madrid, Spain

For all author emails, please log on.

BMC Medical Genetics 2010, 11:32  doi:10.1186/1471-2350-11-32

Published: 25 February 2010



Interleukin (IL)-1β is a potent proinflammatory cytokine markedly overexpressed in the brains of patients with Alzheimer's disease (AD), and also involved in development of atherosclerosis and coronary artery disease. Caspase-1 (CASP1), formerly called IL-1β converting enzyme (ICE), mediates the cleavage of the inactive precursor of IL-1β into the biologically active form. CASP1 genetic variation (G+7/in6A, rs501192) has been associated with susceptibility to myocardial infarction and cardiovascular death risk. We examined the contribution of this gene to the susceptibility for AD.


We examined genetic variations of CASP1 by genotyping haplotype tagging SNPs (htSNPs) (rs501192, rs556205 and rs530537) in a group of 628 Spanish AD cases and 722 controls.


There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls in the overall analysis or after stratification by age, gender or APOE ε4 allele.


Our negative findings in the Spanish population argue against the hypothesis that CASP1 genetic variations are causally related to AD risk.